MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Radiation

Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.

Journal of Thoracic Disease 2019 April [Link] Nelson DB, Rice DC, Mitchell KG, Tsao AS, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Gomez DR, Mehran RJ, Sepesi B Abstract BACKGROUND: Multimodality therapy may prolong survival among resectable malignant pleural mesothelioma (MPM). However, the role of adjuvant radiation remains controversial. We […]

Comments Off on Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.

First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.

Cureus 2019 February 20 [Link] Barsky AR, Cengel KA, Katz SI, Sterman DH, Simone CB Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive disease, with few, if any, curative interventions. While there is growing interest in using immunotherapy and immuno-gene therapy to treat MPM, very limited data currently exist for combining these modalities with […]

Comments Off on First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.

Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.

La Radiologia Medica 2019 April 8 [Link] Trovo M, Franceschini D, Furlan C, Pietrobon F, Vagge S, Farina E, Revelant A, Visani L, Maragna V, Parisi G, Scotti V Abstract PURPOSE: To assess the outcome of malignant pleural mesothelioma patients treated with extra-pleural pneumonectomy (EPP) and adjuvant radiotherapy (RT), using the most advanced radiotherapeutic techniques, […]

Comments Off on Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.

Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.

Journal of Clinical Oncology 2019 March 28 [Link] Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, Edwards JG, Ezhil V, Gilligan D, Hatton M, Jegannathen A, Mansy T, Peake MD, Pemberton L, Rintoul RC, Snee M, Ryder WD, Taylor P, Faivre-Finn C Abstract PURPOSE: Prophylactic irradiation to the chest wall after […]

Comments Off on Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.

Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.

Strahlentherapie and Onkologie 2019 March 26 [Link] Leitzen C, Wilhelm-Buchstab T, Stumpf S, Heimann M, Koch D, Schmeel C, Simon B, Vornholt S, Garbe S, Röhner F2, Schoroth F, Schild HH, Schüller H, Müdder T Abstract PURPOSE: A planning study was performed for helical tomotherapy treatment. We evaluated the maximum achievable protection of organs at risk […]

Comments Off on Tomotherapy in malignant mesothelioma: a planning study to establish dose constraints.

The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.

Annals of Surgical Oncology 2019 February 24 [Link] Lewis GD, Dalwadi SM, Farach A, Brian Butler E, Teh BS Abstract BACKGROUND: Pleural mesothelioma is a rare but aggressive form of cancer. Local recurrence represents the majority of treatment failures and overall survival (OS) outcomes remain dismal. Adding locoregional treatment with radiotherapy after surgical resection has […]

Comments Off on The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma.

Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.

Casopis Lekaru Ceskych 2019 Winter [Link] Klos D, Riško J, Stašek M, Loveček M, Hanuliak J, Skalický P, Lemstrová R, Mohelníková BD, Študentová H, Neoral Č, Melichar B. The tumors of the peritoneal surface, both primary and secondary, are associated with a very poor prognosis and rapid progression through conventional oncology treatment including systemic chemotherapy, […]

Comments Off on Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.

Malignant Peritoneal Mesothelioma: Treatment Options and Survival.

Anticancer Research 2019 February [Link] Salo SAS, Ilonen I, Laaksonen S, Myllärniemi M, Salo JA, Rantanen T Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPeM) is a rare type of cancer with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. Treatment and survival of patients with MPeM have […]

Comments Off on Malignant Peritoneal Mesothelioma: Treatment Options and Survival.

Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.

European Radiology 2019 January 28 [Link] Halpenny D, Raj M, Rimner A, Zheng J, Capanu M, Ginsberg MS Abstract OBJECTIVE: This study was conducted in order to describe the computed tomography (CT) features of local pleural recurrence in patients with malignant pleural mesothelioma undergoing intensity-modulated pleural radiation therapy (IMPRINT) as part of multimodality treatment. METHODS: […]

Comments Off on Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo.

Experimental and Therapeutic Medicine 2019 January [Link] Ye L, Lou Y, Lu L, Fan X Abstract Non-small cell lung cancer (NSCLC) and mesothelioma are renowned for being diagnosed at a late stage and poor prognosis. Although surgery, chemotherapy, and radiotherapy have yielded successful outcomes, the improvement on the survival rate of NSCLC and mesothelioma have been less marked. […]

Comments Off on Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo.